General
Preferred name
MOXIFLOXACIN
Synonyms
MOXIFLOXACIN HYDROCHLORIDE ()
BAY-128039 ()
Moxifloxacin HCl ()
BAY12-8039 HCl ()
Moxifloxacin (Hydrochloride) ()
BAY 12-8039 ()
BAY 12-8039 (free base) ()
Moxifloxacin (BAY12-8039) HCl ()
Avelox, Avalox,BAY12-8039 HCl ()
BAY12-8039 ()
AL-15469A ()
Moxifloxacin (as hydrochloride) ()
BAY-12-8039 ()
Moxeza ()
Avelox ()
Moxivig ()
Minims ()
Vigamox ()
NSC-758875 ()
Avelox iv ()
Avelox I.V. ()
Zimoxin ()
Moxifloxacin-d4 (hydrochloride) ()
P&D ID
PD010166
CAS
151096-09-2
186826-86-8
Tags
natural product
drug
available
Approved by
FDA
First approval
1999
Drug Status
investigational
approved
Drug indication
Bacterial infection
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Moxifloxacin is a fourth generation fluoroquinolone antibacterial. Compared to earlier generation fluoroquinolones it has expanded activity against Gram-positive bacteria and some atypical pathogens. (GtoPdb)
DESCRIPTION Moxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens; it is one of the most active fluoroquinolones against pneumococci, including penicillin- and macrolide-resistant strains. Moxifloxacin has limited phototoxic potential. In clinical trials, moxifloxacin had clinical success rates of 88-97% and bacteriologic eradication rates of 90-97%. Moxifloxacin is a safe and effective antimicrobial that will be useful for treating acute sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. Moxifloxacin possibly stimulates lipid peroxidation and enhances phagocytosis, as depicted by MDA production and survival prolongation, without being toxic as depicted by white blood cell count. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
7
Compound Sets
26
AdooQ Bioactive Compound Library
A10609
Axon Medchem Screening Library
3306
BOC Sciences Bioactive Compounds
moxifloxacin-cas-151096-09-2-item-84-461963
Cayman Chemical Bioactives
14830
22564
ChEMBL Approved Drugs
CHEMBL1200735
CHEMBL32
ChEMBL Drugs
CHEMBL1200735
CHEMBL32
Drug Repurposing Hub
DrugBank
DB00218
DrugBank Approved Drugs
DB00218
DrugCentral
1854
DrugCentral Approved Drugs
1854
DrugMAP
DMU8V4S
DrugMAP Approved Drugs
DMU8V4S
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101978
Guide to Pharmacology
10915
MedChem Express Bioactive Compound Library
HY-66011
HY-66011A
NCATS Inxight Approved Drugs
U188XYD42P
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Moxifloxacin-hcl
moxifloxacin
TargetMol Bioactive Compound Library
T0331
The Spectrum Collection
VGSC-DB
NA0108
NA0109
External IDs
83
Properties
(calculated by RDKit )
Molecular Weight
401.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
2.37
TPSA
83.8
Fraction CSP3
0.52
Chiral centers
2.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
DNA Damage/DNA Repair
Anti-infection
Target
Topo II
Topo IV
TOP2A
antibiotic
Bacterial
Topoisomerase
Antibiotics,Bacterial
Indication
sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections
Disease Area
otolaryngology, pulmonary, infectious disease
MOA
bacterial DNA gyrase inhibitor
Therapeutic Class
Antibiotics
VGSC Target
Nav1.5
Source data